Search

Your search keyword '"Christofyllakis, Konstantinos"' showing total 7 results
Start Over Author "Christofyllakis, Konstantinos" Database OAIster
7 results on '"Christofyllakis, Konstantinos"'

1. KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials

Author

Kaddu-Mulindwa, Dominic, Altmann, Bettina, Robrecht, Sandra, Ziepert, Morita, Regitz, Evi, Tausch, Eugen, Held, Gerhard, Poeschel, Viola, Lesan, Vadim, Bittenbring, Joerg Thomas, Thurner, Lorenz, Pfreundschuht, Michael, Christofyllakis, Konstantinos, Truemper, Lorenz, Loeffler, Markus, Schmitz, Norbert, Hoth, Markus, Hallek, Michael, Fischer, Kirsten, Stilgenbauer, Stephan, Bewarder, Moritz, Rixecker, Torben Millard, Kaddu-Mulindwa, Dominic, Altmann, Bettina, Robrecht, Sandra, Ziepert, Morita, Regitz, Evi, Tausch, Eugen, Held, Gerhard, Poeschel, Viola, Lesan, Vadim, Bittenbring, Joerg Thomas, Thurner, Lorenz, Pfreundschuht, Michael, Christofyllakis, Konstantinos, Truemper, Lorenz, Loeffler, Markus, Schmitz, Norbert, Hoth, Markus, Hallek, Michael, Fischer, Kirsten, Stilgenbauer, Stephan, Bewarder, Moritz, and Rixecker, Torben Millard

Abstract

Background The addition of rituximab to chemotherapy has substantially improved outcomes for patients with B-cell malignancies. The mechanisms of action of rituximab include activation of natural killer cells. Killer-cell immunoglobulin-like receptors (KIRs) mediate natural killer cell function through interaction with HLA. We evaluated the clinical impact of KIR-HLA genotypes on rituximab-containing therapy. Methods For this post-hoc analysis, we used data from the RICOVER-60 trial (NCT00052936) as the discovery cohort and the CLL8 trial (NCT00281918) as the validation cohort. RICOVER-60 included patients aged 61-80 years with aggressive B-cell lymphoma treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without rituximab. CLL8 included patients aged 30-81 years with chronic lymphocytic leukaemia treated with chemotherapy (fludarabine and cyclophosphamide; FC) with or without rituximab. We evaluated the KIR and HLA-C status of 519 patients with available blood samples in the RICOVER-60 trial and the KIR2DS1 and HLA-C status of 549 patients with available blood samples in the CLL8 trial, and evaluated their associations with event-free survival (RICOVER-60), progression-free survival, and overall survival (RICOVER-60 and CLL8). Findings In the RICOVER-60 trial, 201 (39%) patients were positive for KIR2DS1, 79 (15%) were homozygous for HLA-C2, and 36 (7%) were positive for KIR2DS1 and homozygous for HLA-C2. In the CLL8 trial, 206 (38%) patients were positive for KIR2DS1, 75 (14%) were homozygous for HLA-C2, and 26 (5%) were positive for KIR2DS1 and homozygous for HLA-C2. In the RICOVER-60 trial, both KIR2DS1 and HLA-C status were identified as independent risk factors for survival. KIR2DS1 positivity, homozygosity for HLA-C2, and subsequent KIR2DS1-HLA-C status were associated with adverse clinical outcome in patients receiving rituximab-containing therapy (event-free survival for patients with KIR2DS1-HLA-C2/C2 vs all other patient

Published
2022

2. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Author

Poeschel, Viola, Held, Gerhard, Ziepert, Marita, Witzens-Harig, Mathias, Holte, Harald, Thurner, Lorenz, Borchmann, Peter, Viardot, Andreas, Soekler, Martin, Keller, Ulrich, Schmidt, Christian, Truemper, Lorenz, Mahlberg, Rolf, Marks, Reinhard, Hoeffkes, Heinz-Gert, Metzner, Bernd, Dierlamm, Judith, Frickhofen, Norbert, Haenel, Mathias, Neubauer, Andreas, Kneba, Michael, Merli, Francesco, Tucci, Alessandra, Brown, Peter de Nully, Federico, Massimo, Lengfelder, Eva, di Rocco, Alice, Trappe, Ralf, Rosenwald, Andreas, Berdel, Christian, Maisenhoelder, Martin, Shpilberg, Ofer, Amam, Josif, Christofyllakis, Konstantinos, Hartmann, Frank, Murawski, Niels, Stilgenbauer, Stephan, Nickelsen, Maike, Wulf, Gerald, Glass, Bertram, Schmitz, Norbert, Altmann, Bettina, Loeffler, Markus, Pfreundschuh, Michael, Poeschel, Viola, Held, Gerhard, Ziepert, Marita, Witzens-Harig, Mathias, Holte, Harald, Thurner, Lorenz, Borchmann, Peter, Viardot, Andreas, Soekler, Martin, Keller, Ulrich, Schmidt, Christian, Truemper, Lorenz, Mahlberg, Rolf, Marks, Reinhard, Hoeffkes, Heinz-Gert, Metzner, Bernd, Dierlamm, Judith, Frickhofen, Norbert, Haenel, Mathias, Neubauer, Andreas, Kneba, Michael, Merli, Francesco, Tucci, Alessandra, Brown, Peter de Nully, Federico, Massimo, Lengfelder, Eva, di Rocco, Alice, Trappe, Ralf, Rosenwald, Andreas, Berdel, Christian, Maisenhoelder, Martin, Shpilberg, Ofer, Amam, Josif, Christofyllakis, Konstantinos, Hartmann, Frank, Murawski, Niels, Stilgenbauer, Stephan, Nickelsen, Maike, Wulf, Gerald, Glass, Bertram, Schmitz, Norbert, Altmann, Bettina, Loeffler, Markus, and Pfreundschuh, Michael

Abstract

Background Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin lymphoma. In the FLYER trial, we assessed whether four cycles of CHOP plus six applications of rituximab are non-inferior to six cycles of R-CHOP in a population of patients with B-cell non-Hodgkin lymphoma with favourable prognosis. Methods This two-arm, open-label, international, multicentre, prospective, randomised phase 3 non-inferiority trial was done at 138 clinical sites in Denmark, Israel, Italy, Norway, and Germany. We enrolled patients aged 18-60 years, with stage I-II disease, normal serum lactate dehydrogenase concentration, ECOG performance status 0-1, and without bulky disease (maximal tumour diameter <7.5 cm). Randomisation was computer-based and done centrally in a 1:1 ratio using the Pocock minimisation algorithm after stratification for centres, stage (I vs II), and extralymphatic sites (no vs yes). Patients were assigned to receive either six cycles of R-CHOP or four cycles of R-CHOP plus two doses of rituximab. CHOP comprised cyclophosphamide (750 mg/m(2)), doxorubicin (50 mg/m(2)), and vincristine (1.4 mg/m(2), with a maximum total dose of 2 mg), all administered intravenously on day 1, plus oral prednisone or prednisolone at the discretion of the investigator (100 mg) administered on days 1-5. Rituximab was given at a dose of 375 mg/m(2) of body surface area. Cycles were repeated every 21 days. No radiotherapy was planned except for testicular lymphoma treatment. The primary endpoint was progression-free survival after 3 years. The primary analysis was done in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of assigned treatment. A non-inferiority margin of -5.5% was chosen. The trial, which is completed, was prospectively registered at ClinicalTrials.gov, NCT00278421. Findings Between Dec 2, 2005, and Oct 7, 2016, 592 patien

Published
2019

3. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Author

Poeschel, Viola, Held, Gerhard, Ziepert, Marita, Witzens-Harig, Mathias, Holte, Harald, Thurner, Lorenz, Borchmann, Peter, Viardot, Andreas, Soekler, Martin, Keller, Ulrich, Schmidt, Christian, Truemper, Lorenz, Mahlberg, Rolf, Marks, Reinhard, Hoeffkes, Heinz-Gert, Metzner, Bernd, Dierlamm, Judith, Frickhofen, Norbert, Haenel, Mathias, Neubauer, Andreas, Kneba, Michael, Merli, Francesco, Tucci, Alessandra, Brown, Peter de Nully, Federico, Massimo, Lengfelder, Eva, di Rocco, Alice, Trappe, Ralf, Rosenwald, Andreas, Berdel, Christian, Maisenhoelder, Martin, Shpilberg, Ofer, Amam, Josif, Christofyllakis, Konstantinos, Hartmann, Frank, Murawski, Niels, Stilgenbauer, Stephan, Nickelsen, Maike, Wulf, Gerald, Glass, Bertram, Schmitz, Norbert, Altmann, Bettina, Loeffler, Markus, Pfreundschuh, Michael, Poeschel, Viola, Held, Gerhard, Ziepert, Marita, Witzens-Harig, Mathias, Holte, Harald, Thurner, Lorenz, Borchmann, Peter, Viardot, Andreas, Soekler, Martin, Keller, Ulrich, Schmidt, Christian, Truemper, Lorenz, Mahlberg, Rolf, Marks, Reinhard, Hoeffkes, Heinz-Gert, Metzner, Bernd, Dierlamm, Judith, Frickhofen, Norbert, Haenel, Mathias, Neubauer, Andreas, Kneba, Michael, Merli, Francesco, Tucci, Alessandra, Brown, Peter de Nully, Federico, Massimo, Lengfelder, Eva, di Rocco, Alice, Trappe, Ralf, Rosenwald, Andreas, Berdel, Christian, Maisenhoelder, Martin, Shpilberg, Ofer, Amam, Josif, Christofyllakis, Konstantinos, Hartmann, Frank, Murawski, Niels, Stilgenbauer, Stephan, Nickelsen, Maike, Wulf, Gerald, Glass, Bertram, Schmitz, Norbert, Altmann, Bettina, Loeffler, Markus, and Pfreundschuh, Michael

Abstract

Background Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin lymphoma. In the FLYER trial, we assessed whether four cycles of CHOP plus six applications of rituximab are non-inferior to six cycles of R-CHOP in a population of patients with B-cell non-Hodgkin lymphoma with favourable prognosis. Methods This two-arm, open-label, international, multicentre, prospective, randomised phase 3 non-inferiority trial was done at 138 clinical sites in Denmark, Israel, Italy, Norway, and Germany. We enrolled patients aged 18-60 years, with stage I-II disease, normal serum lactate dehydrogenase concentration, ECOG performance status 0-1, and without bulky disease (maximal tumour diameter <7.5 cm). Randomisation was computer-based and done centrally in a 1:1 ratio using the Pocock minimisation algorithm after stratification for centres, stage (I vs II), and extralymphatic sites (no vs yes). Patients were assigned to receive either six cycles of R-CHOP or four cycles of R-CHOP plus two doses of rituximab. CHOP comprised cyclophosphamide (750 mg/m(2)), doxorubicin (50 mg/m(2)), and vincristine (1.4 mg/m(2), with a maximum total dose of 2 mg), all administered intravenously on day 1, plus oral prednisone or prednisolone at the discretion of the investigator (100 mg) administered on days 1-5. Rituximab was given at a dose of 375 mg/m(2) of body surface area. Cycles were repeated every 21 days. No radiotherapy was planned except for testicular lymphoma treatment. The primary endpoint was progression-free survival after 3 years. The primary analysis was done in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of assigned treatment. A non-inferiority margin of -5.5% was chosen. The trial, which is completed, was prospectively registered at ClinicalTrials.gov, NCT00278421. Findings Between Dec 2, 2005, and Oct 7, 2016, 592 patien

Published
2019

4. Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA

Author

Poeschel, Viola, Held, Gerhard, Ziepert, Marita, Altmann, Bettina, Witzens-Harig, Mathias, Holte, Harald, Thurner, Lorenz, Viardot, Andreas, Borchmann, Peter, Kanz, Lothar, Keller, Ulrich, Schmidt, Christian, Mahlberg, Rolf, Metzner, Bernd, Marks, Reinhard, Hoeffkes, Heinz-Gert, Christofyllakis, Konstantinos, Amam, Josif, Berdel, Christian, Stilgenbauer, Stephan, Schmitz, Norbert, Truemper, Lorenz, Murawski, Niels, Loeffler, Markus, Pfreundschuh, Michael, Poeschel, Viola, Held, Gerhard, Ziepert, Marita, Altmann, Bettina, Witzens-Harig, Mathias, Holte, Harald, Thurner, Lorenz, Viardot, Andreas, Borchmann, Peter, Kanz, Lothar, Keller, Ulrich, Schmidt, Christian, Mahlberg, Rolf, Metzner, Bernd, Marks, Reinhard, Hoeffkes, Heinz-Gert, Christofyllakis, Konstantinos, Amam, Josif, Berdel, Christian, Stilgenbauer, Stephan, Schmitz, Norbert, Truemper, Lorenz, Murawski, Niels, Loeffler, Markus, and Pfreundschuh, Michael

Published
2018

5. Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA

Author

Poeschel, Viola, Held, Gerhard, Ziepert, Marita, Altmann, Bettina, Witzens-Harig, Mathias, Holte, Harald, Thurner, Lorenz, Viardot, Andreas, Borchmann, Peter, Kanz, Lothar, Keller, Ulrich, Schmidt, Christian, Mahlberg, Rolf, Metzner, Bernd, Marks, Reinhard, Hoeffkes, Heinz-Gert, Christofyllakis, Konstantinos, Amam, Josif, Berdel, Christian, Stilgenbauer, Stephan, Schmitz, Norbert, Truemper, Lorenz, Murawski, Niels, Loeffler, Markus, Pfreundschuh, Michael, Poeschel, Viola, Held, Gerhard, Ziepert, Marita, Altmann, Bettina, Witzens-Harig, Mathias, Holte, Harald, Thurner, Lorenz, Viardot, Andreas, Borchmann, Peter, Kanz, Lothar, Keller, Ulrich, Schmidt, Christian, Mahlberg, Rolf, Metzner, Bernd, Marks, Reinhard, Hoeffkes, Heinz-Gert, Christofyllakis, Konstantinos, Amam, Josif, Berdel, Christian, Stilgenbauer, Stephan, Schmitz, Norbert, Truemper, Lorenz, Murawski, Niels, Loeffler, Markus, and Pfreundschuh, Michael

Published
2018

6. Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL > 60 study of the DSHNHL.

Author

Pfreundschuh, Michael, Christofyllakis, Konstantinos, Altmann, Bettina, Ziepert, Marita, Haenel, Mathias, Viardot, Andreas, Neubauer, Andreas, Held, Gerhard, Truemper, Lorenz, Schmidt, Christian, Kanz, Lothar, Hallek, Michael J., Schmitz, Norbert, Heintges, Tobias, Koelbel, Christian, Schneider, Guenther, Ruebe, Christian, Hellwig, Dirk, Poeschel, Viola, Murawski, Niels, Pfreundschuh, Michael, Christofyllakis, Konstantinos, Altmann, Bettina, Ziepert, Marita, Haenel, Mathias, Viardot, Andreas, Neubauer, Andreas, Held, Gerhard, Truemper, Lorenz, Schmidt, Christian, Kanz, Lothar, Hallek, Michael J., Schmitz, Norbert, Heintges, Tobias, Koelbel, Christian, Schneider, Guenther, Ruebe, Christian, Hellwig, Dirk, Poeschel, Viola, and Murawski, Niels

Published
2017

7. Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL > 60 study of the DSHNHL.

Author

Pfreundschuh, Michael, Christofyllakis, Konstantinos, Altmann, Bettina, Ziepert, Marita, Haenel, Mathias, Viardot, Andreas, Neubauer, Andreas, Held, Gerhard, Truemper, Lorenz, Schmidt, Christian, Kanz, Lothar, Hallek, Michael J., Schmitz, Norbert, Heintges, Tobias, Koelbel, Christian, Schneider, Guenther, Ruebe, Christian, Hellwig, Dirk, Poeschel, Viola, Murawski, Niels, Pfreundschuh, Michael, Christofyllakis, Konstantinos, Altmann, Bettina, Ziepert, Marita, Haenel, Mathias, Viardot, Andreas, Neubauer, Andreas, Held, Gerhard, Truemper, Lorenz, Schmidt, Christian, Kanz, Lothar, Hallek, Michael J., Schmitz, Norbert, Heintges, Tobias, Koelbel, Christian, Schneider, Guenther, Ruebe, Christian, Hellwig, Dirk, Poeschel, Viola, and Murawski, Niels

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results